5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluación de las concentraciones plasmáticas de voriconazol en práctica clínica Translated title: Assessment of plasma voriconazole concentrations in clinical practice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Introducción: Voriconazol presenta una alta variabilidad interindividual en sus concentraciones plasmáticas (Cp). Los objetivos son: (i) describir sus Cp en una cohorte adulta, (ii) estudiar sus potenciales causas de variabilidad y (iii) relacionarlas con las recomendaciones de monitorización farmacocinética actuales. Método: Estudio observacional retrospectivo, incluyendo pacientes con ≥1 determinación de Cp mínima (Cmin) de voriconazol durante 2017. Resultados: Se analizaron 165 Cmin correspondientes a 51 pacientes. La mediana de Cmin fue de 2,4µg/mL (IQR:1,4-3,6), siendo <1µg/mL en 26 casos y >4µg/mL en 34. Se observaron Cmin significativamente superiores en >65 años (p=0,006) y en pacientes con albúmina <27g/L (p<0,001). Siguiendo las recomendaciones de monitorización de las Cp de voriconazol según la guía ESCMID-ECMM-ERS, se detectarían el 91,1% de Cmin que resultaron fuera de intervalo. Conclusiones: Observamos un 36,4% de las Cmin de voriconazol fuera del intervalo óptimo. Identificamos la edad y la concentración de albúmina como factores que influencian las Cp.

          Translated abstract

          Abstract Introduction: Voriconazole presents a high interindividual variability in plasma concentrations. We aimed to: (i) describe plasma voriconazole concentrations (PVC) of an adult cohort, (ii) identify potential causes of variability and (iii) relate them with current pharmacokinetic monitoring recommendations. Method: Observational retrospective study. All patients with at least one determination of PVC during 2017 were included. Results: A total of 165 trough concentrations (Ctrough) were analyzed from 51 patients. The median Ctroughwas 2.4µg/mL (IQR:1.4-3.6). Ctroughwere <1µg/mL in 26 cases and >4 µg/mL in 34. Significantly higher concentrations were observed in patients older than 65 years (p=0.006) and in patients with albumin levels <27g/L (p<0.001). Following PVC's monitoring recommendation from ESCMID-ECMM-ERS's guideline, we would detect the 91.1% of Ctrough out of the interval. Conclusions: We observed 36.4% of PVC outside of its optimal range. We identified age and albumin concentration as factors that influence PVC.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

          It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

              The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.
                Bookmark

                Author and article information

                Journal
                ars
                Ars Pharmaceutica (Internet)
                Ars Pharm
                Universidad de Granada (Granada, Granada, Spain )
                2340-9894
                September 2021
                : 62
                : 3
                : 305-314
                Affiliations
                [1] Barcelona orgnameHospital Clínic de Barcelona orgdiv1Área del Medicamento orgdiv2Servicio de Farmacia Spain
                [2] Barcelona orgnameHospital Clínic de Barcelona orgdiv1Centro de Diagnóstico Biomédico orgdiv2Servicio de Bioquímica y Genética Molecular Spain
                Article
                S2340-98942021000300305 S2340-9894(21)06200300305
                10.30827/ars.v62i3.20756
                6c93d191-9319-44fd-91ea-776aa42edf5c

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

                History
                : 04 March 2021
                : 08 April 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 15, Pages: 10
                Product

                SciELO Spain

                Categories
                Originales Breves

                monitorización farmacocinética,voriconazol,antifungal,aspergillosis,clinical practice guideline,plasma concentration,therapeutic drug monitoring,voriconazole,antifúngico,aspergilosis,concentraciones plasmáticas,guías de práctica clínica

                Comments

                Comment on this article